fda warning letters compounded semaglutide telehealth 2024 2025 September 15, 2025: company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines FDA Warns Telehealth Firms Over

Description

Matt Segar, cardiologist and member of our Medical Review Board, says, Its also worth noting that studies also showed an increase in pulmonary embolism, acute kidney injury, and atrial fibrillation.30 Transdermal testosterone treatment doesnt cause the kinds of supratherapeutic peaks you often see with injected testosterone replacements.18 Unfortunately, the creams have their own set of dangers

The vision loss is often most severe upon waking, as blood pressure tends to be lowest during sleep

Lymphatic drainage sessions typically produce immediate improvements in fluid retention and skin texture, with cumulative benefits over a treatment series

Key facts for understanding the device context: Trial structure: Four or more core trials (TRIUMPH-1 through TRIUMPH-4 plus TRIUMPH-Outcomes), enrolling 5,800 or more participants across programs Administration: Subcutaneous injection, once weekly, dose escalation to 12mg maximum TRIUMPH-4 results (December 2025): Participants on 12mg retatrutide lost an average of 28.7% body weight at 68 weeks, versus 2.1% on placebo (Giblin et al., PMID 41090431) Phase 2 comparison: 24.2% body weight loss at 48 weeks on 12mg (Jastreboff et al., NEJM 2023) - a different trial, shorter duration, earlier data TRIUMPH-Outcomes: Active Phase 3 trial (NCT06383390), estimated 10,000 participants, completion February 2029 - investigating cardiovascular outcomes What the Phase 3 Device Disclosure Gap Means Eli Lilly has not disclosed pen device specifications for retatrutide because the drug is not yet approved, and device details are part of the commercial product launch package